Preparation and biological evaluation of cyclopentadienyl-based 99mTc-complexes [(Cp-R)99mTc(CO)3] mimicking benzamides for malignant melanoma targeting

Nuclear Medicine and Biology

Volumn 37, Issue 3, 2010, Pages 255-264

  Peindy N'Dongo, Harmel W ^a   Raposinho, Paula D ^b   Fernandes, Célia ^b   Santos, Isabel ^b   Can, Daniel ^a   Schmutz, Paul ^a   Spingler, Bernhard ^a   Alberto, Roger ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b INSTITUTO TECNOLÓGICO E NUCLEAR   (Portugal)

Author keywords

Bioorganometallic Chemistry; Labelling; Melanoma; Radiopharmaceuticals; Retro Diels Alder; Technetium; Tumor uptake

Indexed keywords

BENZAMIDE DERIVATIVE; CYCLOPENTADIENE N (2 DIETHYLAMINOETHYL) 2 IODOBENZAMIDE CARBONATE TC 99M; CYCLOPENTADIENE N (2 DIETHYLAMINOETHYL) 4 IODOBENZAMIDE; CYCLOPENTADIENE N (2 DIETHYLAMINOETHYL) 4 IODOBENZAMIDE CARBONATE RHENIUM; CYCLOPENTADIENE N (2 DIETHYLAMINOETHYL) 4 IODOBENZAMIDE CARBONATE TC 99M; CYCLOPENTADIENE N (N BENZYLPIPERIDIN 4 YL) 2 IODOBENZAMIDE CARBONATE I 123; CYCLOPENTADIENE N (N BENZYLPIPERIDIN 4 YL) 2 IODOBENZAMIDE CARBONATE RHENIUM; CYCLOPENTADIENE RHENIUM CARBONATE TC 99M; N (2 DIETHYLAMINOETHYL) 2 IODOBENZAMIDE I 123; N (2 DIETHYLAMINOETHYL) 4 IODOBENZAMIDE I 123; N (N BENZYLPIPERIDIN 4 YL) 2 IODOBENZAMIDE I 123; RADIOPHARMACEUTICAL AGENT; RHENIUM COMPLEX; RHENIUM TECHNETIUM TC 99M; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DIELS ALDER REACTION; ELECTROSPRAY MASS SPECTROMETRY; IN VITRO STUDY; INFRARED RADIATION; INTERNALIZATION; ISOTOPE LABELING; MELANOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOACTIVITY; X RAY CRYSTALLOGRAPHY;

ANIMALS; BENZAMIDES; CELL LINE, TUMOR; CYCLOPENTANES; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; ISOTOPE LABELING; MELANOMA; METABOLIC CLEARANCE RATE; MICE; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 77950298117     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.11.006     Document Type: Article

References (47)

1. Camacho L.H., Antonia S., Sosman J., Kirkwood J.M., Gajewski T.F., Redman B., et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009, 27:1075-1081.
2. 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab′)2 fragments. Cancer Res 1985, 45:3378-3387.
3. Larson S.M. Biologic characterization of melanoma tumors by antigen-specific targeting of radiolabeled anti-tumor antibodies. J Nucl Med 1991, 32:287-291.
4. 125I-labelled thiouracil and propylthiouracil in murine melanotic melanomas. Br J Cancer 1982, 46:538-550.
5. Van Langevelde A., Bakker C.N., Broxterman H.J., Journee-De Korver J.G., Kaspersen F.M., Oosterhuis J.A., et al. Potential radiopharmaceuticals for the detection of ocular melanoma: Part I. 5-Iodo-2-thiouracil derivatives. Eur J Nucl Med 1983, 8:45-51.
6. Kloss G., Leven M. Accumulation of radioiodinated tyrosine derivatives in the adrenal medulla and in melanomas. Eur J Nucl Med 1979, 4:179-186.
7. 131I-labeled quinoline and tyrosine derivatives. Eur J Nucl Med 1981, 6:227-233.
8. Michelot J.M., Moreau M.F., Labarre P.G., Madelmont J.C., Veyre A.J., Papon J.M., et al. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med 1991, 32:1573.
9. Michelot J.M., Moreau M.F., Veyre A.J., Bonafous J.F., Bacin F.J., Madelmont J.C., et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). J Nucl Med 1993, 34:1260-1266.
10. 125I]BP: a potential sigma receptor marker for human prostate tumors. Nucl Med Biol 1998, 25:189-194.
11. Chehade F., De Labriolle-Vaylet C., Moins N., Moreau M.F., Papon J., Labarre P., et al. Secondary ion mass spectrometry as a tool for investigating radiopharmaceutical distribution at the cellular level: the example of I-BZA and (14)C-I-BZA. J Nucl Med 2005, 46:1701-1706.
12. Guerquin-Kern J.L., Hillion F., Madelmont J.C., Labarre P., Papon J., Croisy A. Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences. Biomed Eng Online 2004, 3:10.
13. Cachin F., Chezal J.M., Miot-Noirault E., Moins N., Auzeloux P., Vidal A., et al. Nouveaux traceurs TEMP: exemple des traceurs des protéoglycanes et de la mélanine. Médecine Nucléaire 2009, 33:161-167.
14. 125I]-N-(N-benzylpiperidin-4-yl)-4- iodobenzamide, a new sigma receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells. J Med Chem 1994, 37:1737-1739.
15. John C.S., Bowen W.D., Saga T., Kinuya S., Vilner B.J., Baumgold J., et al. A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)4-iodobenzamide. J Nucl Med 1993, 34:2169-2175.
16. Guo Z., Sadler P.J. Metals in medicine. Angew Chem Int Ed 1999, 38:1512-1531.
17. Schwochau K. Technetium radiopharmaceuticals - fundamentals, synthesis, structure, and development. Angew Chem Int Ed 1994, 33:2258-2267.
18. Dilworth J.R., Suzanne J.P. The biomedical chemistry of technetium and rhenium. Chem Soc Rev 1998, 27:43-55.
19. Bowen M.L., Orvig C. 99m-Technetium carbohydrate conjugates as potential agents in molecular imaging. Chem Commun (Camb) 2008, 5077-5091.
20. Bartholoma M., Valliant J., Maresca K.P., Babich J., Zubieta J. Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals. Chem Commun (Camb) 2009, 493-512.
21. 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med 2007, 48:73-80.
22. 3-labeled pyrazolyl-[alpha]-melanocyte-stimulating hormone analog conjugate for melanoma targeting. Nucl Med Biol 2008, 35:91-99.
23. Chen J., Cheng Z., Hoffman T.J., Jurisson S.S., Quinn T.P. Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res 2000, 60:5649-5658.
24. Auzeloux P., Papon J., Azim E.M., Borel M., Pasqualini R., Veyre A., et al. A potential melanoma tracer: synthesis, radiolabeling, and biodistribution in mice of a new nitridotechnetium bis(aminothiol) derivative pharmacomodulated by a N-(diethylaminoethyl)benzamide. J Med Chem 2000, 43:190-198.
25. Eisenhut M., Mohammed A., Mier W., Schonsiegel F., Friebe M., Mahmood A., et al. Melanoma uptake of (99m)Tc complexes containing the N-(2-diethylaminoethyl)benzamide structural element. J Med Chem 2002, 45:5802-5805.
26. 99mTc]Oxotechnetium(V) complexes amine-amide-dithiol chelates with dialkylaminoalkyl substituents as potential diagnostic probes for malignant melanoma. J Med Chem 2001, 44:3132-3140.
27. Top S., El Hafa H., Vessieres A., Quivy J., Vaissermann J., Hughes D.W., et al. Rhenium carbonyl complexes of beta-estradiol derivatives with high affinity for the estradiol receptor: an approach to selective organometallic radiopharmaceuticals. J Am Chem Soc 1995, 117:8372-8380.
28. Salmain M., Gunn M., Gorfti A., Top S., Jaouen G. Labeling of proteins by organometallic complexes of rhenium: I. Synthesis and biological activity of the conjugates. Bioconjugate Chem 1993, 4:425-433.
29. Spradau T.W., Katzenellenbogen J.A. Preparation of cyclopentadienyltricarbonylrhenium complexes using a double ligand-transfer reaction. Organometallics 1998, 17:2009-2017.
30. Minutolo F., Katzenellenbogen J.A. Boronic acids in the three-component synthesis of carbon-substituted cyclopentadienyl tricarbonyl rhenium complexes. J Am Chem Soc 1998, 120:13264-13265.
31. Masi S., Top S., Boubekeur L., Jaouen G., Mundwiler S., Spingler B., et al. Direct synthesis of tricarbonyl(cyclopentadienyl)rhenium and tricarbonyl(cyclopentadienyl)technetium units from ferrocenyl moieties - preparation of 17alpha-ethynylestradiol derivatives bearing a tricarbonyl(cyclopentadienyl)technetium group. Eur J Inorg Chem 2004, 2013-2017.
32. 99mTc with an in situ CO source: application to a serotonergic receptor ligand. Angew Chem Int Ed Engl 2001, 40:3062-3066.
33. Bernard J., Ortner K., Spingler B., Pietzsch H.J., Alberto R. Aqueous synthesis of derivatized cyclopentadienyl complexes of technetium and rhenium directed toward radiopharmaceutical application. Inorg Chem 2003, 42:1014-1022.
34. 99mTc, Re) complexes. J Am Chem Soc 2008, 130:1554-1555.
35. 99mTc, Re) with bioactive functionalities. J Organomet Chem 2009, 694:981-987.
36. Top S., Lehn J.S., Morel P., Jaouen G. Synthesis of cyclopentadienyltricarbonylrhenium(I) carboxylic acid from perrhenate. J Organomet Chem 1999, 583:63-68.
37. Peindy N'Dongo H.W., Neundorf I., Merz K., Schatzschneider U. Synthesis, characterization, X-ray crystallography, and cytotoxicity of a cymantrene keto carboxylic acid for IR labelling of bioactive peptides on a solid support. J Inorg Biochem 2008, 102:2114-2119.
38. 125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide: a high affinity sigma receptor ligand for potential imaging of breast cancer. Cancer Res 1995, 55:3022-3027.
39. 2), an imaging agent for melanoma staging: relation to pigmentation. Nucl Med Biol 2005, 32:451-458.
40. Labarre P., Papon J., Moreau M.F., Moins N., Bayle M., Veyre A., et al. Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent. Melanoma Res 2002, 12:115-121.
41. Pham T.Q., Greguric I., Liu X., Berghofer P., Ballantyne P., Chapman J., et al. Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma. J Med Chem 2007, 50:3561-3572.
42. 123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging. Eur J Nucl Med Mol I 2002, 29:1478-1484.
43. Xcalibur CCD system vers. 2007, Oxford Diffraction Ltd., Oxford, UK. 171.32.
44. Altomare A., Burla M.C., Camalli M., Cascarano G.L., Giacovazzo C., Guagliardi A., et al. SIR97: a new tool for crystal structure determination and refinement. J. Appl. Cryst. 1999, 32:115-119.
45. Sheldrick G.M. A short history of SHELX. Acta Cryst 2008, A64:112-122.
46. Spek A.L. Single-crystal structure validation with the program PLATON. J. Appl. Cryst. 2003, 36:7-13.
47. +. J Am Chem Soc 2001, 123:3135-3136.